| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2015-06-23 | lirilumab and rituximab | chronic lymphocytic leukemia, small lymphocytic leukemia | 2 | BMS (USA - NY) | Cancer - Oncology |
| 2015-06-22 | ISIS-SMN Rx (antisense oligonucleotide targeted to the SMN2 gene) | spinal muscular atrophy | 2 | Isis Pharmaceuticals (USA - CA), now Ionis Pharmaceuticals (USA - CA) | Neuromuscular diseases - Rare diseases - Genetic diseases |
| 2015-06-22 | andexanet alfa and Eliquis® (apixaban) | reversion of the anticoagulant activity of Eliquis® |
3 | Pfizer (USA - NY) BMS (USA - NY) Portola Pharmaceuticals (USA - CA) | Cardiovascular diseases - Hematological diseases |
| 2015-06-22 | PREOB® | osteoporosis |
2a | Bone Therapeutics (Belgium) Erasme University Hospital (Belgium) | Bone diseases - Regenerative medicine |
| 2015-06-19 | RES-529 (8-(1-Hydroxy-ethyl)-2-methoxy-3-(4-methoxy-benzyloxy)-benzo[c]chromen-6-one) | prostate cancer |
preclinical | RestorGenex (USA - IL) | Cancer - Oncology |
| 2015-06-19 | CK-2127107 | 1 | Cytokinetics (USA - CA) | Neuromuscular diseases - Rare diseases | |
| 2015-06-19 | Cyramza® (ramucirumab) | patients with hepatocellular carcinoma who have been previously treated with sorafenib in the first-line setting | 3 | Eli Lilly (USA - IN) | Cancer - Oncology |
| 2015-06-18 | OTS167 | solid tumors metastatic tumors |
1 | OncoTherapy Science (Japan) | Cancer - Oncology |
| 2015-06-18 | CAT -1004 - N-(2-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamido)ethyl)-2-hydroxybenzamide | Duchenne muscular dystrophy (DMD) |
1-2 | Catabasis Pharmaceuticals (USA - MA) | Genetic diseases - Neuromuscular diseases - Rare diseases |
| 2015-06-18 | Alprolix® (eftrenonacog alfa - long-lasting recombinant Factor IX Fc fusion protein (rFIXFc) - BIIB 029) | hemophilia B | 3 - pediatric study | BiogenIdec (USA) Swedish Orphan Biovitrum - SOBI (Sweden) | Hematologic diseases - Genetic diseases - Rare diseases |
| 2015-06-18 | Hemophilia A | Phase 3 | Biogen | ||
| 2015-06-18 | edoxaban | venous thromboembolism (VTE) associated with cancer |
Daiichi Sankyo (Japan) | Cancer - Oncology - Cardiovascular diseases | |
| 2015-06-17 | IMGN529 and rituximab | non-Hodgkin lymphoma | preclinical | Immunogen (USA - MA) | Cancer - Oncology |
| 2015-06-17 | LY2951742 | prevention of migraine headache |
2b | Eli Lilly (USA - IN) | CNS diseases |
| 2015-06-17 | multimeric-001 vaccine (M-001) | influenza |
2 | BiondVax Pharmaceutical (Israel) | Infectious diseases |
| 2015-06-17 | PRX002 | Parkinson's Disease |
1 | Prothena (Ireland) Roche (Switzerland) | Neurodegenerative diseases |
| 2015-06-17 | Adcetris® (brentuximab vedotin) | consolidation therapy immediately following an autologous stem cell transplant (ASCT) in Hodgkin lymphoma (HL) patients at high risk of relapse | 3 | Seattle Genetics (USA - WA) | Cancer - Oncology |
| 2015-06-17 | Xtandi® (enzalutamide) | castration-resistant prostate cancer (CRPC) | Medivation (USA - CA) Astellas (Japan) | Cancer - Oncology | |
| 2015-06-16 | APX005M | solid tumors |
1 | Apexigen (USA - CA) | Cancer - Oncology |
| 2015-06-16 | MIN-202 (JNJ-42847922) | comorbid insomnia related to major depressive disorder (MDD) |
1 | Minerva Neurosciences (USA - MA) Janssen Research & Development, a J&J company (USA - NJ) | CNS diseases - Neurological diseases |
